Skip to main content

Featured

Carney Government Faces First Budget Confidence Test in Commons

                 Prime Minister Mark Carney's budget needs two opposition MPs to either support or abstain it to pass. The House of Commons is set to hold its first confidence vote tied to Prime Minister Mark Carney’s inaugural federal budget on Thursday evening. The vote will focus on a Conservative sub-amendment to a Bloc Québécois amendment, both of which challenge key elements of the government’s fiscal plan. The Liberal government has declared the votes to be matters of confidence , meaning defeat could trigger a federal election. While the stakes are high, the government is expected to survive this initial test thanks to support from the New Democratic Party (NDP) and the Bloc Québécois , who have both signaled they will vote against the Conservative motion. Interim NDP Leader Don Davies confirmed that his caucus of seven MPs will side with the Liberals, ensuring the defeat of the Conservative sub-amendment. However, Davies ...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment